Variability in the response to antiplatelet treatment in diabetes mellitus.

Abstract

Atherothrombosis is a leading cause of death in patients with diabetes mellitus. Among factors contributing to the diabetic prothrombotic state, platelet activation plays a pivotal role. Numerous studies have investigated the benefits of antiplatelet therapy for primary and secondary cardiovascular prevention in diabetic patients. However, there are limited evidences that low-dose aspirin may be effective in this clinical setting. Several disease-specific factors have been identified as potential determinants of aspirin treatment failure. In this review, the main determinants of interindividual variability in response to antiplatelet agents are discussed, with particular emphasis on the pharmacokinetic and pharmacodynamic mechanisms of clinical efficacy and safety of antiplatelet drugs in patients with diabetes mellitus.

• Authors: Giovanni Davì, Natale Vazzana, Simona Sestili
• Journal: Prostaglandins & other lipid mediators (Prostaglandins Other Lipid Mediat) Vol. 98 Issue 3-4 Pg. 48-55 (Aug 2012) ISSN: 1098-8823 [Print] United States
• PMID: 22330860 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2012 Elsevier Inc. All rights reserved.

Chemical References

• Platelet Aggregation Inhibitors
• Thromboxanes

Topics

• Diabetes Complications (drug therapy)
• Diabetes Mellitus (drug therapy, prevention & control)
• Humans
• Platelet Aggregation Inhibitors (therapeutic use)
• Thrombosis (complications, drug therapy)
• Thromboxanes (metabolism)
• Treatment Outcome